Merck reported strong third-quarter earnings with a 13% increase in non-GAAP EPS, driven by key product growth and effective cost management. The pending merger with Schering-Plough is on track, with management expressing confidence in future growth opportunities and significant progress in integration planning. Positive earnings, an optimistic outlook, and momentum towards the merger are likely to positively impact the stock price in the short term.

[1]